Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
In two randomized, open-label trials, the combination of glecaprevir and pibrentasvir given once daily for 8 or 12 weeks achieved high rates of sustained virologic response in patients with HCV genotype 1 or 3 infection who did not have cirrhosis.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2018-01, Vol.378 (4), p.354-369 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 369 |
|---|---|
| container_issue | 4 |
| container_start_page | 354 |
| container_title | The New England journal of medicine |
| container_volume | 378 |
| creator | Zeuzem, Stefan Foster, Graham R Wang, Stanley Asatryan, Armen Gane, Edward Feld, Jordan J Asselah, Tarik Bourlière, Marc Ruane, Peter J Wedemeyer, Heiner Pol, Stanislas Flisiak, Robert Poordad, Fred Chuang, Wan-Long Stedman, Catherine A Flamm, Steven Kwo, Paul Dore, Gregory J Sepulveda-Arzola, Gladys Roberts, Stuart K Soto-Malave, Ruth Kaita, Kelly Puoti, Massimo Vierling, John Tam, Edward Vargas, Hugo E Bruck, Rafi Fuster, Francisco Paik, Seung-Woon Felizarta, Franco Kort, Jens Fu, Bo Liu, Ran Ng, Teresa I Pilot-Matias, Tami Lin, Chih-Wei Trinh, Roger Mensa, Federico J |
| description | In two randomized, open-label trials, the combination of glecaprevir and pibrentasvir given once daily for 8 or 12 weeks achieved high rates of sustained virologic response in patients with HCV genotype 1 or 3 infection who did not have cirrhosis. |
| doi_str_mv | 10.1056/NEJMoa1702417 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1991179192</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1991179192</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-24a8ba3f117955fe6c3b4605019b2483c0161b4cbe67aed0ad09690a1187da713</originalsourceid><addsrcrecordid>eNp1kE1Lw0AQhhdRbK0evcqCeIzOZDeb7FFKbSutevDjGDbJBFKbD3dToTf_g__QX2JKq-DBOcwwzMMz8DJ2inCJEKiru9HtvDYYgi8x3GN9DITwpAS1z_oAfuTJUIseO3JuAV2h1Ies52uhAgG6z-bjJaWmsfRe2K-Pz4cisVS1xnUrz2vLI9419PkL0avjRcUnw2c-pqpu1w1x3FwFn1Y5pW1RV8fsIDdLRye7OWBPN6PH4cSb3Y-nw-uZlwoNredLEyVG5IihDoKcVCoSqSAA1IkvI5ECKkxkmpAKDWVgMtBKg0GMwsyEKAbsfOttbP22ItfGi3plq-5ljFpvtKj9jvK2VGpr5yzlcWOL0th1jBBvwov_hNfxZzvrKikp-6V_0uqAiy1Qli6uaFH-I_oGGxlzNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1991179192</pqid></control><display><type>article</type><title>Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><source>New England Journal of Medicine</source><creator>Zeuzem, Stefan ; Foster, Graham R ; Wang, Stanley ; Asatryan, Armen ; Gane, Edward ; Feld, Jordan J ; Asselah, Tarik ; Bourlière, Marc ; Ruane, Peter J ; Wedemeyer, Heiner ; Pol, Stanislas ; Flisiak, Robert ; Poordad, Fred ; Chuang, Wan-Long ; Stedman, Catherine A ; Flamm, Steven ; Kwo, Paul ; Dore, Gregory J ; Sepulveda-Arzola, Gladys ; Roberts, Stuart K ; Soto-Malave, Ruth ; Kaita, Kelly ; Puoti, Massimo ; Vierling, John ; Tam, Edward ; Vargas, Hugo E ; Bruck, Rafi ; Fuster, Francisco ; Paik, Seung-Woon ; Felizarta, Franco ; Kort, Jens ; Fu, Bo ; Liu, Ran ; Ng, Teresa I ; Pilot-Matias, Tami ; Lin, Chih-Wei ; Trinh, Roger ; Mensa, Federico J</creator><creatorcontrib>Zeuzem, Stefan ; Foster, Graham R ; Wang, Stanley ; Asatryan, Armen ; Gane, Edward ; Feld, Jordan J ; Asselah, Tarik ; Bourlière, Marc ; Ruane, Peter J ; Wedemeyer, Heiner ; Pol, Stanislas ; Flisiak, Robert ; Poordad, Fred ; Chuang, Wan-Long ; Stedman, Catherine A ; Flamm, Steven ; Kwo, Paul ; Dore, Gregory J ; Sepulveda-Arzola, Gladys ; Roberts, Stuart K ; Soto-Malave, Ruth ; Kaita, Kelly ; Puoti, Massimo ; Vierling, John ; Tam, Edward ; Vargas, Hugo E ; Bruck, Rafi ; Fuster, Francisco ; Paik, Seung-Woon ; Felizarta, Franco ; Kort, Jens ; Fu, Bo ; Liu, Ran ; Ng, Teresa I ; Pilot-Matias, Tami ; Lin, Chih-Wei ; Trinh, Roger ; Mensa, Federico J</creatorcontrib><description>In two randomized, open-label trials, the combination of glecaprevir and pibrentasvir given once daily for 8 or 12 weeks achieved high rates of sustained virologic response in patients with HCV genotype 1 or 3 infection who did not have cirrhosis.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1702417</identifier><identifier>PMID: 29365309</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antiviral agents ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Benzimidazoles - adverse effects ; Benzimidazoles - therapeutic use ; Cirrhosis ; Clinical trials ; Drug Administration Schedule ; Drug Combinations ; Female ; Genotype ; Genotype & phenotype ; Genotypes ; Hepacivirus - genetics ; Hepatitis ; Hepatitis C ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Humans ; Imidazoles - adverse effects ; Imidazoles - therapeutic use ; Infections ; Interferon ; Liver cirrhosis ; Male ; Medicine ; Middle Aged ; Patients ; Quinoxalines - adverse effects ; Quinoxalines - therapeutic use ; RNA, Viral - blood ; Sofosbuvir - adverse effects ; Sofosbuvir - therapeutic use ; Sulfonamides - adverse effects ; Sulfonamides - therapeutic use ; Viral Load</subject><ispartof>The New England journal of medicine, 2018-01, Vol.378 (4), p.354-369</ispartof><rights>Copyright © 2018 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-24a8ba3f117955fe6c3b4605019b2483c0161b4cbe67aed0ad09690a1187da713</citedby><cites>FETCH-LOGICAL-c390t-24a8ba3f117955fe6c3b4605019b2483c0161b4cbe67aed0ad09690a1187da713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1702417$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1702417$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29365309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zeuzem, Stefan</creatorcontrib><creatorcontrib>Foster, Graham R</creatorcontrib><creatorcontrib>Wang, Stanley</creatorcontrib><creatorcontrib>Asatryan, Armen</creatorcontrib><creatorcontrib>Gane, Edward</creatorcontrib><creatorcontrib>Feld, Jordan J</creatorcontrib><creatorcontrib>Asselah, Tarik</creatorcontrib><creatorcontrib>Bourlière, Marc</creatorcontrib><creatorcontrib>Ruane, Peter J</creatorcontrib><creatorcontrib>Wedemeyer, Heiner</creatorcontrib><creatorcontrib>Pol, Stanislas</creatorcontrib><creatorcontrib>Flisiak, Robert</creatorcontrib><creatorcontrib>Poordad, Fred</creatorcontrib><creatorcontrib>Chuang, Wan-Long</creatorcontrib><creatorcontrib>Stedman, Catherine A</creatorcontrib><creatorcontrib>Flamm, Steven</creatorcontrib><creatorcontrib>Kwo, Paul</creatorcontrib><creatorcontrib>Dore, Gregory J</creatorcontrib><creatorcontrib>Sepulveda-Arzola, Gladys</creatorcontrib><creatorcontrib>Roberts, Stuart K</creatorcontrib><creatorcontrib>Soto-Malave, Ruth</creatorcontrib><creatorcontrib>Kaita, Kelly</creatorcontrib><creatorcontrib>Puoti, Massimo</creatorcontrib><creatorcontrib>Vierling, John</creatorcontrib><creatorcontrib>Tam, Edward</creatorcontrib><creatorcontrib>Vargas, Hugo E</creatorcontrib><creatorcontrib>Bruck, Rafi</creatorcontrib><creatorcontrib>Fuster, Francisco</creatorcontrib><creatorcontrib>Paik, Seung-Woon</creatorcontrib><creatorcontrib>Felizarta, Franco</creatorcontrib><creatorcontrib>Kort, Jens</creatorcontrib><creatorcontrib>Fu, Bo</creatorcontrib><creatorcontrib>Liu, Ran</creatorcontrib><creatorcontrib>Ng, Teresa I</creatorcontrib><creatorcontrib>Pilot-Matias, Tami</creatorcontrib><creatorcontrib>Lin, Chih-Wei</creatorcontrib><creatorcontrib>Trinh, Roger</creatorcontrib><creatorcontrib>Mensa, Federico J</creatorcontrib><title>Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In two randomized, open-label trials, the combination of glecaprevir and pibrentasvir given once daily for 8 or 12 weeks achieved high rates of sustained virologic response in patients with HCV genotype 1 or 3 infection who did not have cirrhosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Benzimidazoles - adverse effects</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Cirrhosis</subject><subject>Clinical trials</subject><subject>Drug Administration Schedule</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Imidazoles - adverse effects</subject><subject>Imidazoles - therapeutic use</subject><subject>Infections</subject><subject>Interferon</subject><subject>Liver cirrhosis</subject><subject>Male</subject><subject>Medicine</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Quinoxalines - adverse effects</subject><subject>Quinoxalines - therapeutic use</subject><subject>RNA, Viral - blood</subject><subject>Sofosbuvir - adverse effects</subject><subject>Sofosbuvir - therapeutic use</subject><subject>Sulfonamides - adverse effects</subject><subject>Sulfonamides - therapeutic use</subject><subject>Viral Load</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kE1Lw0AQhhdRbK0evcqCeIzOZDeb7FFKbSutevDjGDbJBFKbD3dToTf_g__QX2JKq-DBOcwwzMMz8DJ2inCJEKiru9HtvDYYgi8x3GN9DITwpAS1z_oAfuTJUIseO3JuAV2h1Ies52uhAgG6z-bjJaWmsfRe2K-Pz4cisVS1xnUrz2vLI9419PkL0avjRcUnw2c-pqpu1w1x3FwFn1Y5pW1RV8fsIDdLRye7OWBPN6PH4cSb3Y-nw-uZlwoNredLEyVG5IihDoKcVCoSqSAA1IkvI5ECKkxkmpAKDWVgMtBKg0GMwsyEKAbsfOttbP22ItfGi3plq-5ljFpvtKj9jvK2VGpr5yzlcWOL0th1jBBvwov_hNfxZzvrKikp-6V_0uqAiy1Qli6uaFH-I_oGGxlzNg</recordid><startdate>20180125</startdate><enddate>20180125</enddate><creator>Zeuzem, Stefan</creator><creator>Foster, Graham R</creator><creator>Wang, Stanley</creator><creator>Asatryan, Armen</creator><creator>Gane, Edward</creator><creator>Feld, Jordan J</creator><creator>Asselah, Tarik</creator><creator>Bourlière, Marc</creator><creator>Ruane, Peter J</creator><creator>Wedemeyer, Heiner</creator><creator>Pol, Stanislas</creator><creator>Flisiak, Robert</creator><creator>Poordad, Fred</creator><creator>Chuang, Wan-Long</creator><creator>Stedman, Catherine A</creator><creator>Flamm, Steven</creator><creator>Kwo, Paul</creator><creator>Dore, Gregory J</creator><creator>Sepulveda-Arzola, Gladys</creator><creator>Roberts, Stuart K</creator><creator>Soto-Malave, Ruth</creator><creator>Kaita, Kelly</creator><creator>Puoti, Massimo</creator><creator>Vierling, John</creator><creator>Tam, Edward</creator><creator>Vargas, Hugo E</creator><creator>Bruck, Rafi</creator><creator>Fuster, Francisco</creator><creator>Paik, Seung-Woon</creator><creator>Felizarta, Franco</creator><creator>Kort, Jens</creator><creator>Fu, Bo</creator><creator>Liu, Ran</creator><creator>Ng, Teresa I</creator><creator>Pilot-Matias, Tami</creator><creator>Lin, Chih-Wei</creator><creator>Trinh, Roger</creator><creator>Mensa, Federico J</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20180125</creationdate><title>Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection</title><author>Zeuzem, Stefan ; Foster, Graham R ; Wang, Stanley ; Asatryan, Armen ; Gane, Edward ; Feld, Jordan J ; Asselah, Tarik ; Bourlière, Marc ; Ruane, Peter J ; Wedemeyer, Heiner ; Pol, Stanislas ; Flisiak, Robert ; Poordad, Fred ; Chuang, Wan-Long ; Stedman, Catherine A ; Flamm, Steven ; Kwo, Paul ; Dore, Gregory J ; Sepulveda-Arzola, Gladys ; Roberts, Stuart K ; Soto-Malave, Ruth ; Kaita, Kelly ; Puoti, Massimo ; Vierling, John ; Tam, Edward ; Vargas, Hugo E ; Bruck, Rafi ; Fuster, Francisco ; Paik, Seung-Woon ; Felizarta, Franco ; Kort, Jens ; Fu, Bo ; Liu, Ran ; Ng, Teresa I ; Pilot-Matias, Tami ; Lin, Chih-Wei ; Trinh, Roger ; Mensa, Federico J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-24a8ba3f117955fe6c3b4605019b2483c0161b4cbe67aed0ad09690a1187da713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Benzimidazoles - adverse effects</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Cirrhosis</topic><topic>Clinical trials</topic><topic>Drug Administration Schedule</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Imidazoles - adverse effects</topic><topic>Imidazoles - therapeutic use</topic><topic>Infections</topic><topic>Interferon</topic><topic>Liver cirrhosis</topic><topic>Male</topic><topic>Medicine</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Quinoxalines - adverse effects</topic><topic>Quinoxalines - therapeutic use</topic><topic>RNA, Viral - blood</topic><topic>Sofosbuvir - adverse effects</topic><topic>Sofosbuvir - therapeutic use</topic><topic>Sulfonamides - adverse effects</topic><topic>Sulfonamides - therapeutic use</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zeuzem, Stefan</creatorcontrib><creatorcontrib>Foster, Graham R</creatorcontrib><creatorcontrib>Wang, Stanley</creatorcontrib><creatorcontrib>Asatryan, Armen</creatorcontrib><creatorcontrib>Gane, Edward</creatorcontrib><creatorcontrib>Feld, Jordan J</creatorcontrib><creatorcontrib>Asselah, Tarik</creatorcontrib><creatorcontrib>Bourlière, Marc</creatorcontrib><creatorcontrib>Ruane, Peter J</creatorcontrib><creatorcontrib>Wedemeyer, Heiner</creatorcontrib><creatorcontrib>Pol, Stanislas</creatorcontrib><creatorcontrib>Flisiak, Robert</creatorcontrib><creatorcontrib>Poordad, Fred</creatorcontrib><creatorcontrib>Chuang, Wan-Long</creatorcontrib><creatorcontrib>Stedman, Catherine A</creatorcontrib><creatorcontrib>Flamm, Steven</creatorcontrib><creatorcontrib>Kwo, Paul</creatorcontrib><creatorcontrib>Dore, Gregory J</creatorcontrib><creatorcontrib>Sepulveda-Arzola, Gladys</creatorcontrib><creatorcontrib>Roberts, Stuart K</creatorcontrib><creatorcontrib>Soto-Malave, Ruth</creatorcontrib><creatorcontrib>Kaita, Kelly</creatorcontrib><creatorcontrib>Puoti, Massimo</creatorcontrib><creatorcontrib>Vierling, John</creatorcontrib><creatorcontrib>Tam, Edward</creatorcontrib><creatorcontrib>Vargas, Hugo E</creatorcontrib><creatorcontrib>Bruck, Rafi</creatorcontrib><creatorcontrib>Fuster, Francisco</creatorcontrib><creatorcontrib>Paik, Seung-Woon</creatorcontrib><creatorcontrib>Felizarta, Franco</creatorcontrib><creatorcontrib>Kort, Jens</creatorcontrib><creatorcontrib>Fu, Bo</creatorcontrib><creatorcontrib>Liu, Ran</creatorcontrib><creatorcontrib>Ng, Teresa I</creatorcontrib><creatorcontrib>Pilot-Matias, Tami</creatorcontrib><creatorcontrib>Lin, Chih-Wei</creatorcontrib><creatorcontrib>Trinh, Roger</creatorcontrib><creatorcontrib>Mensa, Federico J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zeuzem, Stefan</au><au>Foster, Graham R</au><au>Wang, Stanley</au><au>Asatryan, Armen</au><au>Gane, Edward</au><au>Feld, Jordan J</au><au>Asselah, Tarik</au><au>Bourlière, Marc</au><au>Ruane, Peter J</au><au>Wedemeyer, Heiner</au><au>Pol, Stanislas</au><au>Flisiak, Robert</au><au>Poordad, Fred</au><au>Chuang, Wan-Long</au><au>Stedman, Catherine A</au><au>Flamm, Steven</au><au>Kwo, Paul</au><au>Dore, Gregory J</au><au>Sepulveda-Arzola, Gladys</au><au>Roberts, Stuart K</au><au>Soto-Malave, Ruth</au><au>Kaita, Kelly</au><au>Puoti, Massimo</au><au>Vierling, John</au><au>Tam, Edward</au><au>Vargas, Hugo E</au><au>Bruck, Rafi</au><au>Fuster, Francisco</au><au>Paik, Seung-Woon</au><au>Felizarta, Franco</au><au>Kort, Jens</au><au>Fu, Bo</au><au>Liu, Ran</au><au>Ng, Teresa I</au><au>Pilot-Matias, Tami</au><au>Lin, Chih-Wei</au><au>Trinh, Roger</au><au>Mensa, Federico J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2018-01-25</date><risdate>2018</risdate><volume>378</volume><issue>4</issue><spage>354</spage><epage>369</epage><pages>354-369</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In two randomized, open-label trials, the combination of glecaprevir and pibrentasvir given once daily for 8 or 12 weeks achieved high rates of sustained virologic response in patients with HCV genotype 1 or 3 infection who did not have cirrhosis.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>29365309</pmid><doi>10.1056/NEJMoa1702417</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2018-01, Vol.378 (4), p.354-369 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_1991179192 |
| source | MEDLINE; EZB Electronic Journals Library; New England Journal of Medicine |
| subjects | Adult Aged Aged, 80 and over Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Benzimidazoles - adverse effects Benzimidazoles - therapeutic use Cirrhosis Clinical trials Drug Administration Schedule Drug Combinations Female Genotype Genotype & phenotype Genotypes Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Imidazoles - adverse effects Imidazoles - therapeutic use Infections Interferon Liver cirrhosis Male Medicine Middle Aged Patients Quinoxalines - adverse effects Quinoxalines - therapeutic use RNA, Viral - blood Sofosbuvir - adverse effects Sofosbuvir - therapeutic use Sulfonamides - adverse effects Sulfonamides - therapeutic use Viral Load |
| title | Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A53%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glecaprevir%E2%80%93Pibrentasvir%20for%208%20or%2012%20Weeks%20in%20HCV%20Genotype%201%20or%203%20Infection&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Zeuzem,%20Stefan&rft.date=2018-01-25&rft.volume=378&rft.issue=4&rft.spage=354&rft.epage=369&rft.pages=354-369&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa1702417&rft_dat=%3Cproquest_cross%3E1991179192%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1991179192&rft_id=info:pmid/29365309&rfr_iscdi=true |